RecruitingPHASE1, PHASE2NCT06122831
A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)
Studying Primary myelofibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Intervention
- TQ05105 Tablets(drug)
- Enrollment
- 92 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2027
Study locations (22)
- Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
- Guangxi Zhuang Autonomous Region People's Hospital, Nanning, Guangxi, China
- Cangzhou People's Hosipital, Cangzhou, Hebei, China
- Affiliated Hospital of Chengde Medical College, Chengde, Hebei, China
- North China of Science and Technology University Affiliated Hospital, Tangshan, Hebei, China
- Xingtai People's Hospital, Xingtai, Hebei, China
- The First Hospital of Harbin, Harbin, Heilongjiang, China
- Henan Cancer Hospital, Zhengzhou, Henan, China
- Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan, Hubei, China
- Union Hospital Tongji College Huazhong Unizersity of Science And Technology, Wuhan, Hubei, China
- Wuhan University Zhongnan Hospital, Wuhan, Hubei, China
- The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China
- The Public Hospital of Wuxi, Wuxi, Jiangsu, China
- The First Hospital of Jilin University, Changchun, Jilin, China
- Xi 'An Jiaotong University Second Affiliated Hospital, Xi'an, Shaanxi, China
- +7 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06122831 on ClinicalTrials.govOther trials for Primary myelofibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07104799Momelotinib During and After HCT in MyelofibrosisMassachusetts General Hospital
- RECRUITINGPHASE3NCT07317700A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk MyelofibrosisChengdu Zenitar Biomedical Technology Co., Ltd
- RECRUITINGPHASE1, PHASE2NCT07128381Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)M.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT06887803A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK InhibitorsiOnctura
- RECRUITINGPHASE1, PHASE2NCT07281781Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone MarrowUniversity of California, Irvine
- ACTIVE NOT RECRUITINGNCT07342712Clinical Trail to Evaluate the Effect of Long-term Treatment With Gecacitinib on Myelofibrosis and Gene Mutation LevelsFirst Affiliated Hospital of Zhejiang University
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06909136A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With MyelofibrosisSuzhou Junjing BioSciences Co., Ltd.
- RECRUITINGPHASE2NCT06770842Ropeginterferon Alfa 2b Plus Ruxolitinib for MyelofibrosisThe University of Hong Kong